Bionote Targets Annual Revenue of About KRW 300 Billion by FY2030
Bitget2026/10/22 09:01- Bionote's Oct. 22, 2026, value-up plan targets fiscal 2030 revenue of about KRW 300 billion.
- Targets also include a 30% operating margin and a price-to-book ratio of 1.2 times.
- Growth plans include expanding diagnostic platforms, increasing US subsidiary sales and establishing local production capacity.
- The strategy also calls for entering the antibody therapeutics market and expanding the life sciences business.
- Shareholder returns include maintaining stable dividends, with cancellation of 500,000 treasury shares annually under consideration for three years starting in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A 6% yield is not "extremely cheap"! Fidelity throws cold water: Long-term inflation and debt risks are key, and US Treasuries may no longer serve as a "safe haven" for the stock market.
In the view of Salman Ahmed, Head of Global Macro and Strategic Asset Allocation at Fidelity International, even if the 10-year US Treasury yield rises to 6%, it would not be considered "extremely cheap."

Japan's exports in October rose 20.5% year-on-year, exceeding expectations; semiconductor equipment exports surged nearly 50%.
Official data released by Japan on Wednesday showed that exports in October rose by 20.5% year-on-year, ending a two-month slowdown.

BUZZ-Ardent Health shares fall after launching secondary public offering
BUZZ - Ardent Health shares fall after launching secondary public offering